UNSPSC 51171900: Antiulcer and related gastrointestinal GI drugs

This classification denotes various agents with different action mechanisms used to treat or ameliorate peptic ulcer or irritation of the gastrointestinal tract. this has included antibiotics to treat helicobacter infections; histamine h2 antagonists to reduce gastric acid secretion; and antacids for symptomatic relief.

UNSPSC 51171900 Antiulcer and related gastrointestinal GI drugs is a Class code that in recent state and local procurement activity does not reflect purchasing aligned with its nominal scope. The single recent opportunity tagged under this code — Collin County Community Supervision and Corrections Department's RFP 2026-327 for offender specimen collection and drug testing services — involves immunoassay screening, confirmatory testing by LC/MS/MS or GC/MS, and alternative testing methodologies including oral fluid and hair analysis. This work falls squarely within forensic and clinical laboratory testing services, not antiulcer or gastrointestinal pharmaceutical procurement. The code shows no recent activity consistent with actual acquisition of medications or drug products in that therapeutic category by state or local health departments, correctional systems, school districts, or other public bodies.

The mismatch between the code's pharmaceutical scope and the forensic testing opportunity suggests either miscoding by the issuing procurement office or a data artifact. Collin County's RFP 2026-327, posted September 25, 2026 with a proposal due date of July 23, 2026 (a date in the past relative to the post date), seeks a qualified contractor to staff two collection sites in Plano and McKinney, operate an IVR system for randomized testing notifications, and deliver approximately 25,031 tests annually under a two-year base contract with three optional one-year renewals, estimated at $600,000. The successful vendor must hold SAMHSA, Texas DPS, or CAP lab certification and maintain pricing on a per-test basis with no surcharges. Code activity under the gastrointestinal pharmaceutical scope remains unsupported by available recent opportunities.